Healthcare does not wait for the Federal Reserve to announce a rate cut. Cancer treatment, diabetes management, and essential surgery rarely come with a “let’s wait until borrowing gets cheaper” option. That gives pharmaceutical stocks, biotechnology companies, and medical device makers a durable source of demand—even if their share prices occasionally need a checkup of their own.
Demographics add another reason to watch the sector. The World Health Organization projects that one in six people worldwide will be aged 60 or older by 2030. An aging population supports long-term demand for chronic disease treatments and medical technology, putting healthcare stocks on the radar of investors seeking both growth potential and defensive characteristics. Getting older may be unavoidable; finding businesses positioned to meet those needs takes a little more homework.
Big Business Beyond the Pharmacy Counter
The healthcare sector has considerably more going on than the medicine cabinet suggests. Oncology, immunology, cardiovascular medicine, and diabetes care serve different patient populations, giving diversified drugmakers several potential revenue streams. For investors, that means a company’s prospects may depend on an entire treatment portfolio rather than one heavily advertised product.
Some of these businesses also involve science that makes ordinary manufacturing look fairly straightforward. Many biologic medicines are produced using living systems, including animal cells or microorganisms. These treatments are generally larger and more complex than conventional small-molecule drugs. This is precision manufacturing with living ingredients, where consistency matters far more than a catchy product slogan.
That complexity also explains why biosimilars deserve a closer look. They are highly similar versions of approved biologic medicines, rather than the straightforward copies associated with traditional generic drugs. The distinction matters when assessing competition, development costs, and how long an established treatment can keep generating attractive sales.
When Inflation Runs Hot, Investors Look for a Steadier Pulse
Interest-rate uncertainty gives investors another reason to examine profitability and market sensitivity. September consumer inflation reached 3.7%, while producer prices rose 1.3% during the month. On October 16, Federal Reserve Chair Kevin Warsh offered no fresh rate signals at an IMF event in Bangkok, leaving investors to continue their favorite guessing game—predicting the Fed’s next move.
Against that backdrop, profitable healthcare companies with beta below 1 offer a useful starting point for research. A lower beta indicates historically smaller price movements relative to the broader market. It can appeal to investors who would prefer their portfolios to have fewer dramatic episodes.
Still, low beta is no financial vaccine. Drug approvals, patent expirations, pricing pressure, and acquisition costs can all reshape earnings and send share prices lower. Essential products help support demand, but investors still need to examine what they are paying for the business.
Looking for more healthcare investing ideas? Explore 5 Best Micro Cap Healthcare Stocks to Watch Today and Top 6 Best AI Healthcare Stocks to Buy Today.
Our Methodology
For 5 No-Brainer Healthcare Stocks to Buy Now, we used the Finviz screener to identify U.S.-listed companies with market capitalizations of at least $200 billion, beta below 1, and net profit margins above 10%, using October 16, 2026 data. We ranked the five selections by beta, placing the lowest at No. 1 and using larger market capitalization to break ties. The screen prioritizes scale, profitability, and historically lower market sensitivity; the “no-brainer” label still leaves room for doing the homework.
Novartis AG (NYSE:NVS) ranks 4th in our list of 5 No-Brainer Healthcare Stocks to Buy Now. Click HERE to find out other stocks on the list.
Novartis AG (NYSE:NVS)
Market Cap $275.17 billion | Beta 0.43 | Net Profit Margin 23.29%
Fast-Growing Medicines Help Offset an Older Franchise’s Decline
Novartis AG (NYSE: NVS) offers a useful reminder that modest companywide growth can hide much faster expansion underneath. Second-quarter 2026 net sales reached $14.41 billion, increasing 3% in U.S. dollars and 1% at constant currencies.
Several priority medicines moved considerably faster. At constant currencies, Kisqali sales increased 43%, Kesimpta rose 32%, Scemblix jumped 89%, and Pluvicto advanced 43%. Those gains show why investors examining pharmaceutical stocks need to look beyond the headline revenue figure.
The offset was substantial. Entresto sales declined 50% in U.S. dollars to approximately $1.18 billion. Stronger newer products therefore had to replace lost revenue before contributing much additional growth at the group level.
Profitability also deserves a closer reading. Quarterly net income fell 19% to approximately $3.26 billion, while free cash flow declined 12% to $5.6 billion. Management reaffirmed its full-year outlook, anticipating low-single-digit net sales growth and a low-single-digit decline in core operating income.
The investment thesis rests on the changing revenue mix. Continued expansion from priority brands could strengthen the earnings base over time, but the transition needs to appear in consolidated profits as well as individual product sales. A healthy supplied net profit margin is encouraging; it does not eliminate the work required to replace declining revenue.
Ranking Rationale
Novartis AG (NYSE: NVS) takes fourth place with a supplied beta of 0.43 and a 23.29% net profit margin. Its beta matches the third-ranked company at the displayed precision, so the order preserves the supplied ranking. The rounded beta figures alone do not establish a meaningful difference in market sensitivity between those two positions.
YOU MUST READ THIS: Top 6 Small-Cap Healthcare Stocks to Buy Right Now
Disclosure: No material interests to disclose. This article was originally published on BioTech HealthX.
